Cambrex Reports Third Quarter 2013 Financial Results - Strong increase in third quarter Sales and EBITDA -

- Full year 2013 guidance tightened -

- Company to host conference call at 8:30 a.m. ET on November 1, 2013 -

EAST RUTHERFORD, N.J., Nov. 1, 2013 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports results for the third quarter ended September 30, 2013.

Highlights

  • Third quarter sales increased to $78.0 million from $59.8 million in the third quarter of 2012. 
  • Third quarter EBITDA increased to $17.0 million compared to $9.6 million in the same period last year (see table at the end of this release). 
  • Debt, net of cash was $76.0 million at the end of the third quarter, an increase of $8.5 million during the quarter. 
  • 2013 full year sales and EBITDA guidance ranges tightened, increased lower end of ranges (see Financial Expectations section below).

"We are very pleased with our strong third quarter financial results and narrowed our full year guidance range, increasing the lower end of the range for both sales and EBITDA, reflecting our confidence in expected full year results," commented Steven M. Klosk, President and Chief Executive Officer of Cambrex.  "Our Charles City, Iowa facility began shipping commercial launch quantities of an API for a key new product candidate and we are currently on schedule to ship higher volumes of this new API than was previously expected for 2013.  As we've indicated in recent quarters, we continue to see strong demand for late stage custom development products."

Third Quarter 2013 Operating Results
Sales of $78.0 million were 30.3% higher compared to the same period last year, including the favorable impact of foreign exchange of 1.8%.  The increase was primarily due to higher sales of a large phase 3 product and certain branded active pharmaceutical ingredients ("APIs"), partially offset by lower sales of generic APIs and products utilizing the Company's drug delivery technology.          

Gross margins increased to 32.0% from 31.0% compared to the same period last year.  This increase was primarily due to increased sales and production volumes partially offset by higher production costs. 

Selling, general and administrative ("SG&A") expenses were $11.1 million compared to $11.9 million in the same period last year.  The decrease was mainly due to lower personnel expenses.

Research and development expenses were $2.6 million compared to $2.3 million in the same period last year. 

Operating profit increased to $11.3 million from $4.3 million in the same period last year. The increase in operating profit was primarily the result of higher gross profit and lower selling, general and administrative expenses.  EBITDA was $17.0 million compared to $9.6 million in the same period last year. 

Net interest expense was $0.7 million compared to $0.6 million in the same period last year.  This increase was primarily a result of higher average debt.

Equity in losses of partially-owned affiliates, for the Company's portion of Zenara's loss, was $0.5 million compared to $0.6 million in the same period last year.  These amounts include amortization expense of $0.2 million for the third quarters of 2013 and 2012. 

The provision for income taxes was $3.8 million and resulted in an effective tax rate of 37.7%. 

Income from continuing operations was $6.3 million or $0.20 per share compared to $2.0 million or $0.07 per share in the same period last year. 

Loss from discontinued operations, net of tax, was $2.7 million and represents estimated increases in expected future environmental investigation and remediation costs at two former operating sites.

Capital expenditures and depreciation were $6.2 million and $5.7 million, respectively, compared to $5.3 million for both capital expenditures and depreciation in the same period last year. 

Financial Expectations – Continuing Operations
The Company expects that full year 2013 sales, excluding the impact of foreign currency, will increase between 9% and 12% over 2012, versus the Company's previous expectation of a full year 2013 sales increase of between 8% and 12%.  In addition, the Company expects that full year 2013 adjusted EBITDA will be between $64 and $68 million, an increase of 11% to 18% over 2012, versus the Company's previous expectation of a full year 2013 adjusted EBITDA between $62 and $68 million

The Company began recording tax expense on U.S. income for the first time in several years beginning in 2013 and currently estimates that its 2013 consolidated effective tax rate will be between 32% and 36%.  Due to certain beneficial tax attributes, the Company currently expects to pay only a small amount of cash taxes in the U.S. for the next few years.  The tax rate and amount of cash taxes paid will be sensitive to the geographic mix of income, and quarterly effective tax rates may be volatile. 

Capital expenditures for 2013 are expected to be approximately $40 to $43 million, an increase from the previous range of $36 to $40 million, and depreciation is expected to be $22 to $24 million in 2013, unchanged from prior guidance.

These financial expectations are for continuing operations and exclude the impact of any potential acquisitions, restructuring activities and outcomes of tax disputes, and do not reflect the Company's stake in Zenara, which is accounted for using the equity method.

The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's third quarter 2013 Form 10-Q is filed with the SEC.

Conference Call and Webcast
A conference call to discuss the Company's third quarter 2013 results will begin at 8:30 a.m. Eastern Time on Friday, November 1, 2013 and last approximately 45 minutes.  Those wishing to participate should call 1-888-510-1765 for domestic and +719-325-2494 for international.  Please use the pass code 8702967 and call approximately 10 minutes prior to start time.  A webcast will be available on the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Friday, November 8, 2013 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 8702967 to access the replay. 

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.  

Forward Looking Statements
This document contains "forward-looking statements," including statements regarding expected performance, especially those set forth under the heading "Financial Expectations – Continuing Operations," including the Company's expectation that full year 2013 sales, excluding the impact of foreign currency, will increase between 9% and 12% versus 2012, that full year 2013 adjusted EBITDA will be between $64 and $68 million, that capital expenditures will be approximately $40 to $43 million, that depreciation will be $22 to $24 million in 2013, that the Company currently expects to pay only a small amount of cash taxes in the U.S. for the next few years, and that its estimated tax rate will be between 32% and 36%.  These and other forward looking statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described, or incorporated by reference, in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2012, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products, continued demand in the U.S. for late stage clinical products, as well as risks relating to the build-up of inventory and capital expenditures that have been made in advance of revenue for a Phase 3 supply agreement signed during 2012 including that the customer's product may not obtain the necessary regulatory approvals to commercialize the product, that anticipated quantities may be meaningfully reduced, and that the Company may not be able to meet customer timelines for production if, among other variables, the Company's new large scale GMP manufacturing facility in Charles City, Iowa does not continue to perform as anticipated.

For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2012, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

Use of Non-GAAP Financial Measures
EBITDA is a non-GAAP financial measure, which the Company defines as operating profit plus depreciation and amortization expense.  Other companies may have a different definition of EBITDA and, therefore, EBITDA may not be comparable with non-GAAP financial measures provided by other companies.  EBITDA should not be considered an alternative to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex's liquidity.  Cambrex uses EBITDA as one of several metrics to assess and analyze its operational results and trends.  Cambrex also believes it is useful to investors because it is a common operating performance metric as well as a metric routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation from U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

 

CAMBREX CORPORATION

Statements of Profit and Loss

For the Quarters Ended September 30, 2013 and 2012

(in thousands, except per-share data)













2013



2012





% of





% of



Amount


Sales



Amount


Sales











Gross Sales

$

77,992




$

59,841



     Commissions, Allowances and Rebates


547





456



Net Sales


77,445





59,385













     Other


7





(175)













Net Revenues


77,452





59,210













     Cost of Goods Sold


52,486


67.3%



40,679


68.0%











Gross Profit


24,966


32.0%



18,531


31.0%











Operating Expenses










     Selling, General and Administrative Expenses


11,128


14.3%



11,910


19.9%

     Research and Development Expenses


2,588


3.3%



2,347


3.9%

Total Operating Expenses


13,716


17.6%



14,257


23.8%











Operating Profit


11,250


14.4%



4,274


7.1%











Other Expenses:










     Interest Expense, net


664





576



     Other Expenses, net


5





72



     Equity in Losses of Partially-Owned Affiliates


508





630













Income Before Income Taxes


10,073


12.9%



2,996


5.0%











     Provision for Income Taxes


3,799





975













Income from Continuing Operations

$

6,274


8.0%


$

2,021


3.4%











Loss from Discontinued Operations, Net of Tax


(2,700)





(332)













Net Income

$

3,574


4.6%


$

1,689


2.8%











Basic Earnings/(Loss) per Share of Common Stock:










   Income from Continuing Operations


$         0.21





$       0.07



   Loss from Discontinued Operations, Net of Tax


$       (0.09)





$      (0.01)



   Net Income


$         0.12





$       0.06













Diluted Earnings/(Loss) per Share of Common Stock:









   Income from Continuing Operations


$         0.20





$       0.07



   Loss from Discontinued Operations, Net of Tax


$       (0.08)





$      (0.01)



   Net Income


$         0.12





$       0.06













Weighted Average Shares Outstanding










     Basic


30,184





29,711



     Diluted


31,052





30,587



 

CAMBREX CORPORATION

Statements of Profit and Loss

For the Nine Months Ended September 30, 2013 and 2012

(in thousands, except per-share data)













2013



2012





% of





% of



Amount


Sales



Amount


Sales











Gross Sales

$

214,201




$

207,542



     Commissions, Allowances and Rebates


775





1,772



Net Sales


213,426





205,770













     Other


1,714





801













Net Revenues


215,140





206,571













     Cost of Goods Sold


146,174


68.2%



137,167


66.1%











Gross Profit


68,966


32.2%



69,404


33.4%











Operating Expenses










     Selling, General and Administrative Expenses


32,854


15.3%



33,829


16.3%

     Research and Development Expenses


7,547


3.5%



7,297


3.5%

Total Operating Expenses


40,401


18.9%



41,126


19.8%











     Gain on Sale of Asset


4,680


2.2%



-


-











Operating Profit


33,245


15.5%



28,278


13.6%











Other Expenses:










     Interest Expense, net


1,647





1,905



     Other Expenses, net


11





96



     Equity in Losses of Partially-Owned Affiliates


1,657





1,221













Income Before Income Taxes


29,930


14.0%



25,056


12.1%











     Provision for Income Taxes


9,095





6,069













Income from Continuing Operations

$

20,835


9.7%


$

18,987


9.1%











Loss from Discontinued Operations, Net of Tax


(3,819)





(332)













Net Income

$

17,016


7.9%


$

18,655


9.0%











Basic Earnings/(Loss) per Share of Common Stock:










   Income from Continuing Operations


$         0.69





$       0.64



   Loss from Discontinued Operations, Net of Tax


$       (0.12)





$      (0.01)



   Net Income


$         0.57





$       0.63













Diluted Earnings/(Loss) per Share of Common Stock:









   Income from Continuing Operations


$         0.67





$       0.63



   Loss from Discontinued Operations, Net of Tax


$       (0.12)





$      (0.01)



   Net Income


$         0.55





$       0.62













Weighted Average Shares Outstanding










     Basic


30,081





29,645



     Diluted


30,938





30,140













 

CAMBREX CORPORATION

Consolidated Balance Sheets

As of September 30, 2013 and December 31, 2012

(in thousands)















September 30,



December 31,

Assets


2013



2012







Cash and Cash Equivalents

$

25,092


$

23,551

Trade Receivables, net


53,996



43,094

Inventories, net


101,407



71,221

Prepaid Expenses and Other Current Assets


18,179



6,104

  Total Current Assets


198,674



143,970







Property, Plant and Equipment, net


166,990



151,815

Goodwill


38,019



37,312

Intangible Assets, net


3,993



4,091

Investments in and Advances to Partially-Owned Affiliates


13,023



15,094

Deferred Income Taxes


37,079



39,262

Other Non-Current Assets


8,667



2,924







  Total Assets

$

466,445


$

394,468







Liabilities and Stockholders' Equity












Accounts Payable

$

32,044


$

27,612

Deferred Revenue


11,541



11,570

Accrued Expenses and Other Current Liabilities


43,257



43,844

  Total Current Liabilities


86,842



83,026







Long-Term Debt


101,050



64,000

Deferred Income Taxes


19,458



18,577

Accrued Pension Benefits


54,382



55,373

Other Non-Current Liabilities


18,383



10,195







  Total Liabilities

$

280,115


$

231,171







  Stockholders' Equity

$

186,330


$

163,297







  Total Liabilities and Stockholders' Equity

$

466,445


$

394,468













 

CAMBREX CORPORATION

Reconciliation of GAAP to non-GAAP Results

For the Quarters and Nine Months Ended September 30, 2013 and 2012

(in thousands)









Third Quarter 2013



Third Quarter 2012








Operating Profit

$

11,250



$

4,274








Depreciation and Amortization


5,745




5,324








EBITDA

$

16,995



$

9,598


























































Nine Months 2013



Nine Months 2012








Operating Profit

$

33,245



$

28,278








Gain on Sale of Asset


(4,680)




-








Adjusted Operating Profit


28,565




28,278








Depreciation and Amortization


16,631




16,134








Adjusted EBITDA

$

45,196



$

44,412








 

SOURCE Cambrex Corporation



RELATED LINKS
http://www.cambrex.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.